Briefing Note: 014

13/06/2023

Update to Recommendations in NCIS.Chart





Further Information


Any comments or further information, please contact ncis@cancercontrol.ie

- > The NCIS Implementation Group have approved a request for change to add two recommendations to the list of recommendations in the conference form in NCIS.Chart:
 - Molecular Biomarker Testing
 - Other Recommendation

Molecular Biomarker Testing

A Health Technology Assessment¹ by HIQA to provide advice to the Health Service Executive on alternative gene expression profiling (GEP) tests to Oncotype DX® advised consideration should be given to collecting data on GEP tests, linked to treatment and patient characteristics and outcomes, as part of a national database.

To facilitate documentation of this in NCIS, the NCIS Implementation Group have approved the addition of a recommendation for "Molecular biomarker testing". This recommendation type is further specified with two options; 1) Oncotype DX Gene Expression Test, and 2) Other.



Other Recommendation

The NCIS MDM User Group proposed a request for change to add a new recommendation of "Other Recommendation" to capture recommendations that do not fit the existing agreed options. The information box can be used to further specify this with free text.

Results of the conference				
No.	Recommendation type	Recommendation/location	Information	
1.	Other Recommendation	in-house external not specified		[^]

¹ A rapid health technology assessment of gene expression profiling tests for guiding the use of adjuvant chemotherapy in early stage invasive breast cancer -February 2023 Health Information and Quality Authority https://www.hiqa.ie/reports-and-publications/health-technology-assessment/rapid-hta-gene-expression-profiling-tests